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Abstract
A notable minority of patients experience persistent postsurgical pain and some of these
patients consequently have prolonged exposure to opioids. Risk factors for prolonged opioid use
after surgery include preoperative opioid use, anxiety, substance abuse, and alcohol abuse. The
window to intervene and potentially prevent persistent opioid use after surgery is short and may
best be accomplished by both surgeon and anesthesiologist working together. Anesthesiologists
in particular are well positioned in the perioperative surgical home model to affect multiple
aspects of the perioperative experience, including tailoring intraoperative medications and
providing consultation for possible discharge analgesic regimens that can help minimize opioid
use. Multimodal analgesia protocols reduce opioid consumption and thereby reduce exposure to
opioids and theoretically the risk of persistent use. Regional anesthesia and analgesia techniques
also reduce opioid consumption. Although many patients will recover without difficulty, the
small minority who do not should receive customized care which may involve multiple office
visits or consultation of a pain specialist. Enhanced recovery pathways are useful in optimizing
outcomes after surgery.

Key Words: Total joint arthroplasty; persistent opioid use after surgery; multimodal analgesia;
opioid epidemic; persistent post-surgical pain
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Introduction
While many patients will follow a normal and expected course of recovery from pain
following joint replacement surgery, a portion of patients will present with severe pain of longer
duration often leading to prolonged opioid exposure. These patients are at risk of developing
long term opioid use and potentially substance use disorder. By specific evaluation prior to
surgery and the incorporation of opioid-reducing strategies preoperatively, intraoperatively and
postoperatively within the context of enhanced recovery pathways, we may best address the
needs of these challenging patients. Orthopaedic surgeons and their colleagues in orthopaedic
anesthesia have been early adopters of enhanced recovery pathways and have realized many
benefits for their patients. However, these pathways often neglect patients who are outliers and
who need customized analgesic approaches. We will present the special considerations for these
patients. The best treatment is likely prevention followed by early intervention.

The effect of patient and surgical characteristics on the risk of persistent opioid use after surgery
in opioid-naïve patients
Although not every patient taking opioids persistently beyond a month after surgery can
be predicted, there are several common characteristics that can be discussed in further detail. Sun
et al [1] performed a retrospective database analysis using administrative claims data over a 12year period. A group of opioid-naïve patients who underwent one of 11 different surgery types
was compared to a matched cohort of opioid-naïve patients who did not undergo surgery. The
incidence of chronic opioid use after total knee arthroplasty (TKA) according to their definition
was 1.41% compared to 0.136% in their control sample. Among demographic factors they found
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that both male gender and age greater than 50 years were associated with increased odds of
taking chronic opioids, defined as having 10 or more opioid prescriptions or taking opioids for
more than 120 days (excluding the first 90 postoperative days) during the first year after surgery.
The association with male gender may seem somewhat surprising as previous studies have linked
the risk of chronic postsurgical pain (CPSP) to younger females [2,3]. However, this is a key
distinction, that is, the difference between CPSP and chronic opioid use. Although some patients
who develop CPSP ultimately will end up taking chronic opioids, this is not always the case and
the patient factors may be different.
Several other patient factors were identified by Sun et al [1], including preoperative drug
abuse, alcohol abuse, depression, as well as use of medications including benzodiazepines and
antidepressants. Similarly, Brummett et al [4] in another large database study of surgical patients
found that preoperative tobacco use, alcohol and substance use disorders, anxiety, and pain
disorders were associated with chronic opioid use after surgery. In their study, the incidence of
persistent opioid use was more liberally defined as the filling of one opioid prescription between
90 and 180 days. Not surprisingly their reported incidence of persistent opioid use was higher
than that of Sun et al (about 6% for Brummett et al). It should also be noted that Brummett et al
did not include any major orthopedic procedures in their cohort.
One might surmise that more painful surgeries would be more likely to result in persistent
opioid use. Although Sun et al [1] found this to be the case, Brummett et al [4] found no
difference in persistent opioid use between major and minor surgery. The patient risk factors
stated above, including anxiety, alcohol and substance use disorder, suggest that persistent
surgical pain alone is not the driving force behind abnormally prolonged opioid use. Many of the
reasons have yet to be elucidated. The implications of Brummett et al, namely that minor surgery
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resulted in just as high incidence of persistent opioid use as major surgery, are concerning. If that
is indeed the case then there is an effect of opioid molecules themselves, at least in susceptible
patients, that is powerful enough that even minor surgery can lead to prolonged use.

Patient characteristics associated with persistent opioid use after total knee arthroplasty in
opioid-tolerant patients
Patients taking opioids chronically prior to surgery represent a completely different
scenario and present a perioperative challenge as they are more likely to consume higher doses
of opioids and rate their pain intensity higher in the first 48 h after TKA than their opioid-naïve
counterparts [5]. Namba et al [6] retrospectively studied 23,726 patients who underwent TKA in
the Kaiser Permanente system; 60% of the patients in this cohort were taking opioids at the time
of surgery. However, although they did report co-morbidities that included 11.6% with chronic
back pain and 13.6% with nonspecific chronic pain, the diagnoses for which patients were taking
preoperative opioids were not available. At 3 months after surgery 41.2% of patients were still
taking opioids; this dropped to 30% at 9-12 months postoperatively. This is more than 5 times
the rate of persistent opioid use reported by Brummett et al at the same time postoperatively [4].
Preoperative use of opioids is consistently shown to be linked to persistent opioid use
after surgery. A large database study of patients who underwent upper extremity surgery
revealed that patients who had received opioids prior to surgery were more likely to fill opioid
prescriptions and receive refills after surgery [7]. In a study of a mixed surgical population,
preoperative opioid use was once again a risk factor for persistent use [8]. As the preoperative
opioid daily dose increases, the risk of persistent use also increases [9]. Possible patient risk
factors for persistent opioid use are shown in Table 1.
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Does intraoperative management affect the risk of persistent opioid use after surgery?
Anesthesiologists can and should play a key role in guiding patients through the
perioperative experience. The Perioperative Surgical Home (PSH) model of care, which is a
“patient-centered and physician-led multidisciplinary and team-based system of coordinated care
that guides the patient throughout the entire surgical experience [10],” is one way to empower
anesthesiologists in making decisions that positively impact patient care. Anesthesiologists have
the training and experience to evaluate patient disease and create a perioperative plan best for
each patient. The PSH will be discussed in more detail in the following sections. When it comes
to intraoperative management, there is evidence that even brief exposure to high doses of
remifentanil, a potent, very short-acting opioid, is associated with chronic pain [11]. Chia et al
[12] demonstrated that high-dose intraoperative fentanyl can lead to greater postoperative pain
intensity and opioid consumption, including the induction of acute opioid tolerance. Opioidinduced hyperalgesia can develop rapidly, including during the perioperative period when
relatively brief periods of opioid exposure occur [13]. The use of regional anesthesia for total
joint arthroplasty (TJA) is one way to reduce perioperative opioid use as well as morbidity and
should be considered for all patients without contraindications. Patients who undergo TJA with
regional anesthesia (neuraxial or peripheral nerve block) have improved postoperative pain and
fewer opioid-related adverse effects, presumably from reduced opioid consumption [14].
Regional anesthesia also may reduce the incidence of surgical site infections, pulmonary
complications, and length of stay [15,16]. Anesthesiologists are in an ideal position to
recommend regional anesthesia and help develop clinical protocols that feature it. This has been
advocated by some as a component of an effective multimodal analgesic protocol for TKA [17].
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Role of Enhanced Recovery Pathways in Reducing Opioid Usage
Efforts to improve perioperative care of patients using evidence-based medicine has led
to the implementation of protocols that minimize opioid usage. Adopted in the United Kingdom
and Europe, enhanced recovery after surgery (ERAS) protocols use multidisciplinary pathways
designed to standardize care and apply evidence-based medicine to all phases of the
perioperative period [18].
Opioid reduction via use of multimodal analgesics, peripheral nerve blocks, and neuraxial
analgesia is often included to help meet recovery and discharge goals. Use of these techniques in
ERAS protocols has been associated with early return of bowel function [19], less overall
complications, and earlier discharge after colorectal surgery [20]. A study by Scott et al [21]
demonstrated that the use of spinal anesthesia in an ERAS protocol for TJA was associated with
earlier mobilization and decreased postoperative stay by 1 day.
Implementation of ERAS pathways has met resistance. Protocols are becoming more
complex, with a variable amount of supportive evidence for each element [22]. While studies
show that strict adherence an ERAS protocol leads to a lower risk of postoperative complications
and postoperative symptoms that delay discharge, compliance varies, especially in the
postoperative period [23].
In the United States, hospitals and national organizations including the American Society
of Anesthesiologists (ASA) have advocated adopting the PSH model. Both ERAS and PSH
protocols are designed to decrease variability in perioperative care and can reduce opioid
consumption in the perioperative period. One difference is the PSH is more patient-centered,
allowing for patient-specific customization in treatment of challenging patient groups [24].
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Within the PSH framework, custom analgesic plans can be formulated for patients with chronic
pain, particularly those who are medically complex or opioid tolerant.

Reducing Opioid Prescriptions
Careful consideration of an analgesic regimen to treat acute pain is important in the
inpatient period and similar principles should be applied upon patient discharge. The Centers for
Disease Control and Prevention (CDC) recognize that chronic opioid use often begins with
treatment of acute pain [25]. This is reflected in current prescription guidelines stating that
“treatment of acute pain with opioids should be for the shortest duration possible” [26]. Ideally,
clinicians should prescribe the lowest effective dose of an immediate-release opioid with a
duration less than three days and no more than seven days.
Encouraging trends in opioid prescriptions were observed in the past few years [27].
From 2014-16, prescriptions decreased 5% annually. The number of patients taking opioids per
100 Americans has dropped from 20.7 to 19.1 and the average morphine milligram equivalent
has decreased from 59.7 to 47.1. However, the number of patients per 100 Americans receiving
chronic pain prescriptions (prescription with an opioid supply >30 days) has risen sharply in the
past 10 years.
A study from Levy et al [28] evaluating opioid prescriptions by medical specialties from
2007-12 showed that specialties associated with the treatment of painful conditions were more
likely to prescribe opioids. While overall prescription rates rose in this time period, they
stabilized after 2010. Specialties more likely to manage chronic pain, such as pain management,
physical medicine/rehabilitation, internal medicine and family medicine, experienced steady
increases in opioid prescriptions (Figure 1). Other specialties associated more with acute pain
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conditions, such as surgeons, emergency medicine physicians, and dentists, decreased
prescription rates before and after 2010.
After the declaration of the opioid crisis as a ‘national emergency,’ external entities have
taken measures to decrease the prescription and consumption of these medications. The Drug
Enforcement Administration mandated a 20% reduction in opioid manufacturing for 2018 [29].
CVS, the largest retail pharmacy company in the U.S., has recently changed its opioid dispensing
guidelines [30]. Opioid-naïve patients with acute pain are limited to a 7-day supply of the
medication. Daily dosage will be limited based on the strength of the opioid, and they will
require use of immediate-release opioids before dispensing the extended-release formulation.

The effect of duration of opioid prescription after surgery and risk of persistent use
The duration of opioid prescription a patient initially receives after surgery has a major
impact on the likelihood he or she is still taking opioids months to years later. In its weekly
morbidity and mortality report the CDC presented data from 2006-2015 showing that patients
who received an initial opioid prescription for 10 days had almost a 20% probability of still
taking opioids 1 year later. That probability increased to about 35% at 1 year with a 30-day
supply [26]. From that same report, it is clear that the number of prescriptions in the first episode
of opioid use increases the probability of taking opioids at both 1 and 3 years later, as does
starting a long-acting opioid for the patient as part of the initial prescription. The data included
all opioid prescriptions and not just surgical patients, so the population may not represent
surgical patients or orthopedic patients. However, the message is clear that patients should be
sent home after surgery with the shortest supply of opioids necessary.
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Monitoring Opioid Use After Discharge
Acute pain can be multifactorial with nociceptive, visceral, neuropathic, inflammatory or
muscle spasm components [31]. No one medication can treat all components. Formulation of an
optimal analgesic regimen after discharge should cover specific agents to treat these components,
the necessity of opioids, and expected duration of opioid usage.
In the United States, postoperative analgesic prescriptions are traditionally written by
surgeons. However, providing adequate analgesia in the perioperative period and after discharge
is the responsibility of the entire perioperative team. Communication about the optimal analgesic
regimen, monitoring the postoperative pain trajectory (Table 2), and post-discharge opioid use
should occur between the surgeon and anesthesiologist or acute pain physician.

Conclusion
Persistent pain following joint replacement surgery will occur in a subset of patients
placing them at risk for prolonged opioid use and potential long-term opioid exposure and
potential substance use disorder. The exact number following arthroplasty is not known but
overall numbers in general surgery suggest 6-10% will be using opioids at one year following
their procedure. The adoption of enhanced recovery pathways minimizing or eliminating opioids
should be considered standard practice. Furthermore, by carefully identifying potential outliers
for persistent pain and applying customized care, we may further reduce the potential for
persistent opioid use. Clearly, the use of opioids as first-line or primary analgesics for
perioperative pain must be reconsidered.
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Figure legend
Figure 1. Opioid prescriptions from 2007-2012 by specialty
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Table 1. Risk factors for persistent opioid use after surgery
Likely
Preoperative opioid use
Anxiety
Substance abuse
Alcohol abuse
Possible
Tobacco use
Antidepressant use
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Table 2. Recommendations for monitoring the postoperative pain trajectory to ensure minimal
opioid usage and proposed interventions in the case of persistent opioid use.
Phase of Care

Monitoring

Hospital Course

History and physical

Time of Discharge

History and physical

Intervention
Anesthetic/analgesic plan that
minimizes opioid use
•
•
•

Post-discharge (5-7 days)

Post-discharge (3 weeks)

Office Visit
Telemedicine encounter
Phone call

•

Office visit
Telemedicine encounter
Phone call

•
•

•

Multimodal analgesia
Continuous peripheral nerve
blocks (if indicated)
Prescription for 5-7 days of
smallest dose of immediaterelease oral opioids
If pain controlled, continue
with non-opioid medications
If pain uncontrolled, consider
intervention: adding nonopioid medications,
mindfulness, meditation,
consultation with expert in
pain management
Aggressive intervention
Consultation with expert in
pain management
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